[go: up one dir, main page]

CL2009001479A1 - Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide. - Google Patents

Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.

Info

Publication number
CL2009001479A1
CL2009001479A1 CL2009001479A CL2009001479A CL2009001479A1 CL 2009001479 A1 CL2009001479 A1 CL 2009001479A1 CL 2009001479 A CL2009001479 A CL 2009001479A CL 2009001479 A CL2009001479 A CL 2009001479A CL 2009001479 A1 CL2009001479 A1 CL 2009001479A1
Authority
CL
Chile
Prior art keywords
veratrum
alkaloid
plant material
deglycosylated
isolating
Prior art date
Application number
CL2009001479A
Other languages
English (en)
Inventor
Gamini Senerath Jayatilake
Steve L Richheimer
David A Mann
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of CL2009001479A1 publication Critical patent/CL2009001479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Método para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solución acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
CL2009001479A 2008-07-02 2009-06-24 Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide. CL2009001479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7770308P 2008-07-02 2008-07-02

Publications (1)

Publication Number Publication Date
CL2009001479A1 true CL2009001479A1 (es) 2010-01-04

Family

ID=41464684

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001479A CL2009001479A1 (es) 2008-07-02 2009-06-24 Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.

Country Status (14)

Country Link
US (3) US20100003728A1 (es)
EP (1) EP2318027B1 (es)
JP (1) JP5607041B2 (es)
KR (1) KR20110028640A (es)
CN (1) CN102137679B (es)
AR (1) AR074524A1 (es)
AU (1) AU2009266993A1 (es)
BR (1) BRPI0913997A2 (es)
CA (1) CA2729110A1 (es)
CL (1) CL2009001479A1 (es)
IL (1) IL210149A (es)
PE (1) PE20100258A1 (es)
TW (1) TW201006484A (es)
WO (1) WO2010002970A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008109829A1 (en) 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Cyclopamine lactam analogs and methods of use thereof
RU2009137014A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Гетероциклические аналоги циклопамина и способы их применения
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
KR20100137416A (ko) * 2007-12-27 2010-12-30 인피니티 파마슈티칼스, 인코포레이티드 암 치료법
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CA2636807A1 (en) * 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
DK2443229T3 (da) * 2009-06-18 2020-03-30 Phyton Holdings Llc Fremstilling af alkaloider med cellekultur fra Veratrum californicum
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
WO2011057222A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN104861034B (zh) * 2014-02-24 2017-04-19 中国人民解放军第二军医大学 环巴胺类似物三元环环巴胺及其衍生物与制备和应用
EP3302428B1 (en) 2015-06-04 2025-10-01 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US6993456B2 (en) * 1999-09-30 2006-01-31 Rockwell Automation Technologies, Inc. Mechanical-electrical template based method and apparatus
US6456928B1 (en) * 2000-12-29 2002-09-24 Honeywell International Inc. Prognostics monitor for systems that are subject to failure
EP1541579A1 (en) * 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
EP2082037A1 (en) * 2006-09-29 2009-07-29 Vib Vzw Plant cell lines established from the medicinal plant veratrum californicum
CA2636807A1 (en) * 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine

Also Published As

Publication number Publication date
EP2318027B1 (en) 2022-02-02
US20100003728A1 (en) 2010-01-07
IL210149A (en) 2016-03-31
KR20110028640A (ko) 2011-03-21
AR074524A1 (es) 2011-01-26
JP2011526921A (ja) 2011-10-20
AU2009266993A1 (en) 2010-01-07
US20160168193A1 (en) 2016-06-16
CN102137679A (zh) 2011-07-27
EP2318027A2 (en) 2011-05-11
BRPI0913997A2 (pt) 2015-10-20
WO2010002970A2 (en) 2010-01-07
CN102137679B (zh) 2013-04-24
JP5607041B2 (ja) 2014-10-15
CA2729110A1 (en) 2010-01-07
US20190263852A1 (en) 2019-08-29
TW201006484A (en) 2010-02-16
EP2318027A4 (en) 2016-12-28
PE20100258A1 (es) 2010-04-21
WO2010002970A3 (en) 2010-05-06
IL210149A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CL2009001479A1 (es) Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
CL2009000672A1 (es) Metodo para la extraccion de componentes, en particular lipidos de material biologico, que comprende un pretratamiento y una extraccion posterior en un disolvente organico; y unidad analitica para llevar a cabo el metodo, que comprende un equipo de pretratamiento y un equipo de extraccion.
CL2012003413A1 (es) Metodo para aumentar la tolerancia al estres medioambiental abiotico de una planta; metodo para mejorar calidad y/o rendimiento y/o el vigor de un cultivo vegetal; metodo para reducir los daños en una planta provocados por uno o mas factores de estres medioambiental abiotico, que comprenden la aplicacion de al menos un ciclopropeno en el agua de irrigación de la planta.
AR087534A1 (es) Aparato de recepcion, metodo de recepcion, programa y sistema de procesamiento de informacion
MX2019005692A (es) Procesos para producir lipidos.
AR080478A1 (es) Metodos para extraer y aislar constituyentes de un material ceculosico
CL2007001453A1 (es) Metodo para enviar comunicacion de inter-proximidad en un arbol de anillos en un sistema de computador facilitando la comunicacion de una federacion rendezvous.
AR081558A1 (es) Extraccion de lipidos de celulas y productos provenientes de ellos
MX387673B (es) Dispositivos de aislamiento con una matriz de anodo y un catodo de fibra.
CL2012000820A1 (es) Compuestos derivados de maitansina (maitansinoides); procedimiento de preparación de un conjugado que comprende poner en contacto un anticuerpo en disolución con alguno de dichos compuestos y separar el anticuerpo conjugado que se forma; dicho conjugado; disolución acuosa que lo comprende; y su uso como anticancerígeno.
BRPI0916498A2 (pt) Método de produção de biomassa enriquecida com carboidratos e método de fragmentação simultânea e extração seletiva de lignina
CL2012001117A1 (es) Composicion que comprende celulas madres multipotenciales del arbol biliar de un mamífero; método para obtener células multipotentes de un mamífero capaz de diferenciarse en multiples linajes endotérmicos.
AR090853A1 (es) Metodo y sistema para extraer yemas de un tallo de una planta graminacea
CL2011002669A1 (es) Tabaco tratado para un articulo para fumar en que el tabaco porta diluyente y material de barrera en donde el diluyente se aplica al tabaco antes que o simultaneamente con el material de barrera, articulo para fumar; y metodo para producir el tabaco tratado.
AR097882A1 (es) Método para procesar la biomasa que contiene celulosa
CL2013000371A1 (es) Conversor electromecanico que incluye un elastomero dielectrico que incluye un polimero de poliuretano; su procedimiento de produccion; y uso de un elastomero dielectrico que sirve como un accionador, sensor y/o generador en un conversor electromecanico.
CL2012002498A1 (es) Método para extraer lípidos a partir de suspensiones acuosas de biomasa, en particular suspensiones algales desestabilizadas, usando solventes inmiscibles en agua.
CL2013000105A1 (es) Fertilizante acuoso organico que comprende extracto de semilla oleaginosa y suero; método para elaborar dicho fertilizante.
AR094785A1 (es) Producción de cuero
MX2021000023A (es) Composicion y metodo para el ahorro de opioides.
UY35986A (es) Método mejorado para la producción de extractos de ginkgo
BR112014029436A2 (pt) método de obtenção de extrato rico em rutina a partir de uma planta; e extrato rico em rutina de uncaria elliptica
CL2019000887A1 (es) Extracto de planta impregnado de alulosa y método de preparación para el mismo.
CL2014000451A1 (es) Metodo para sedar, anestesiar o someter a eutanasia un organismo acuático que comprende poner en contacto dicho organismo con linalol; composición que comprende linalol y al menos un solvente o surfactante.
CL2007001871A1 (es) Proceso para la produccion de peroxido de hidrogeno que comprende poner en contacto una solucion de alimentacion organica que contiene peroxido de hidrogeno con un solvente de extraccion que contiene menos de un 30% en peso de agua y asi obtener un extracto que contenga peroxido de hidrogeno.